Magdalina Yanakieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Magdalina Yanakieva has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Diana Marinova
Med Univ, Univ Hosp, Dept Neurol, Pleven, Bulgaria
2 shared publications - Emilia Ovcharova
Med Univ, Univ Hosp, Dept Neurol, Pleven, Bulgaria
2 shared publications - Maya Danovska
Department of Neurology, University Hospital, Medical University, Pleven, Bulgaria
2 shared publications - Nicholas Shepherd
Northampton Gen Hosp, Dept Acute Med, Northampton, England
1 shared publication
Latest Publications
- 20 May 2024
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 30 (2) , 5527-5532
NEUROFILAMENTS AS A POTENTIAL BIOMARKER IN PATIENTS WITH MULTIPLE SCLEROSIS: A REVIEW OF LITERATURE
Background: Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system (CNS) characterized by demyelination, axonal damage and loss of neurons. Its growing incidence has determined the need for more intensive research towards effective models for managing disease progression and evaluation of treatment response. Finding clinically relevant biomarkers has been a significant challenge. Purpose: This review aims to summarize the findings from current relevant literature sources on neurofilaments as a potential biomarker of diagnostic and prognostic value in patients with MS. Results: Recently, neurofilaments have been identified as the most promising and informative biomarkers of axonal damage and loss. Neurofilament concentration demonstrates a strong association with the disease course, activity and progression, disability accumulation and response to disease-modifying treatment. A significant correlation with future relapse rates, symptom worsening and risk of conversion from clinically isolated syndrome (CIS) to definite MS has also been established. Several MS therapies have demonstrated a substantial reduction in neurofilament levels upon treatment initiation. Conclusion: The results available from real-world studies and clinical trials regarding neurofilaments as a reliable predictor and indicator of MS disease course are encouraging. They have consistently proven to be of utility if integrated into the diagnostic and therapeutic algorithm of MS patients. This review encompasses undeniable data confirming the considerable potential of neurofilaments for becoming the first globally verified biomarker for MS. The accessibility, safety, low cost and possibility for serial evaluation make the neurofilaments the perfect component to be implemented in routine clinical tests for MS.
- 20 May 2024
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 30 (2) , 5527-5532
NEUROFILAMENTS AS A POTENTIAL BIOMARKER IN PATIENTS WITH MULTIPLE SCLEROSIS: A REVIEW OF LITERATURE
Background: Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease of the central nervous system (CNS) characterized by demyelination, axonal damage and loss of neurons. Its growing incidence has determined the need for more intensive research towards effective models for managing disease progression and evaluation of treatment response. Finding clinically relevant biomarkers has been a significant challenge. Purpose: This review aims to summarize the findings from current relevant literature sources on neurofilaments as a potential biomarker of diagnostic and prognostic value in patients with MS. Results: Recently, neurofilaments have been identified as the most promising and informative biomarkers of axonal damage and loss. Neurofilament concentration demonstrates a strong association with the disease course, activity and progression, disability accumulation and response to disease-modifying treatment. A significant correlation with future relapse rates, symptom worsening and risk of conversion from clinically isolated syndrome (CIS) to definite MS has also been established. Several MS therapies have demonstrated a substantial reduction in neurofilament levels upon treatment initiation. Conclusion: The results available from real-world studies and clinical trials regarding neurofilaments as a reliable predictor and indicator of MS disease course are encouraging. They have consistently proven to be of utility if integrated into the diagnostic and therapeutic algorithm of MS patients. This review encompasses undeniable data confirming the considerable potential of neurofilaments for becoming the first globally verified biomarker for MS. The accessibility, safety, low cost and possibility for serial evaluation make the neurofilaments the perfect component to be implemented in routine clinical tests for MS.
- 5 June 2023
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 29 (2) , 4943-4946
TUMEFACTIVE MULTIPLE SCLEROSIS: A DIAGNOSTIC ENIGMA. A CASE REPORT
- 5 June 2023
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 29 (2) , 4943-4946
TUMEFACTIVE MULTIPLE SCLEROSIS: A DIAGNOSTIC ENIGMA. A CASE REPORT